Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


11.03.2019

3 Eur J Gastroenterol Hepatol
1 Gastroenterology
1 Hepatology
1 J Gastroenterol
1 J Med Virol
1 J Virol
1 Lancet Infect Dis
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Eur J Gastroenterol Hepatol

  1. DARWEESH SK, AbdElAziz RA, Abd-ElFatah DS, AbdElazim NA, et al
    Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001385.
    PubMed     Text format     Abstract available


  2. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy: Erratum.
    Eur J Gastroenterol Hepatol. 2019;31:549.
    PubMed     Text format    

  3. SHEHATA HH, Elfert AA, Abdin AA, Soliman SM, et al
    Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy.
    Eur J Gastroenterol Hepatol. 2018;30:1476-1481.
    PubMed     Text format     Abstract available


    Gastroenterology

  4. HAMDANE N, Juhling F, Crouchet E, El Saghire H, et al
    HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Gastroenterology. 2019 Mar 2. pii: S0016-5085(19)32506.
    PubMed     Text format     Abstract available


    Hepatology

  5. KWONG AJ, Kim WR, Flemming JA
    De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30045.
    PubMed     Text format     Abstract available


    J Gastroenterol

  6. TAKAGUCHI K, Toyoda H, Tsutsui A, Suzuki Y, et al
    Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    J Gastroenterol. 2019 Mar 8. pii: 10.1007/s00535-019-01568.
    PubMed     Text format     Abstract available


    J Med Virol

  7. POORDAD F, Bennett M, Sepe TE, Cohen E, et al
    Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with HCV genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    J Med Virol. 2019 Mar 6. doi: 10.1002/jmv.25448.
    PubMed     Text format     Abstract available


    J Virol

  8. SAHUC ME, Sahli R, Riviere C, Pene V, et al
    Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus RNA Replication.
    J Virol. 2019 Mar 6. pii: JVI.02009-18. doi: 10.1128/JVI.02009.
    PubMed     Text format     Abstract available


    Lancet Infect Dis

  9. BURKI T
    Eliminating hepatitis C.
    Lancet Infect Dis. 2019;19:246-247.
    PubMed     Text format    


    PLoS One

  10. GANOVA-RAEVA L, Dimitrova Z, Alexiev I, Punkova L, et al
    HCV transmission in high-risk communities in Bulgaria.
    PLoS One. 2019;14:e0212350.
    PubMed     Text format     Abstract available

  11. KENNEDY K, Graham SM, Arora N, Shuhart MC, et al
    Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis.
    PLoS One. 2018;13:e0204031.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: